Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 12/20 | 0.61 |
| ▸ | FAP | Q12884 | 11/20 | 0.61 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.57 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 3/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25893450 | 0.95 | PREP (0.59) | PREPFAPDPP8DPP9ALDH1A1 | |
| SCHEMBL25893533 | 0.92 | PREP (0.60) | PREPFAPDPP8DPP9DPP4 | |
| SCHEMBL25893992 | 0.91 | PREP (0.63) | PREPFAPDPP8DPP9DPP4 | |
| SCHEMBL25891234 | 0.91 | PREP (0.63) | PREPFAPDPP8DPP9DPP4 | |
| SCHEMBL25890644 | 0.91 | PREP (0.58) | PREPFAPDPP8DPP9DPP4 | |
| SCHEMBL25893452 | 0.91 | PREP (0.62) | PREPFAPDPP8DPP9TSHR | |
| SCHEMBL25893152 | 0.89 | PREP (0.56) | PREPFAPDPP8DPP9FOLH1 | |
| SCHEMBL23876868 | 0.88 | PREP (0.68) | PREPFAPDPP8DPP9DPP4 | |
| SCHEMBL25892737 | 0.86 | PREP (0.57) | PREPFAPDPP8DPP9DPP4 | |
| SCHEMBL25890336 | 0.86 | PREP (0.66) | PREPFAPDPP8DPP9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE | 2024-06-27 | — | — | US | disclosed |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE | 2024-06-27 | — | — | US | disclosed |
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-10-19 | — | — | US | disclosed |
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-10-19 | — | — | US | disclosed |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | FAP, APC, FIBP | PREP 543/4885FAP 1/4885DPP8 223/4885 |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | FAP, APC, FIBP | PREP 543/4885FAP 1/4885DPP8 223/4885 |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | BCL6B, BCL6, BTD | PREP 2680/4885FAP 1959/4885DPP8 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.